A Head and Neck Cancer Tumor Response-Specific Gene Signature for Cisplatin, 5-Fluorouracil Induction Chemotherapy Fails with Added Taxanes

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Tomkiewicz, Céline ^a,b   Hans, Stéphane ^b,c   Mucchielli, Marie Hélène ^d,e,f   Agier, Nicolas ^d,e,j   Delacroix, Hervé ^d,e,g   Marisa, Laetitia ^d,e,k   Brasnu, Daniel ^b,c   Aggerbeck, Lawrence P ^a,b,d,e   Badoual, Cécile ^b,c,h   Barouki, Robert ^a,b,i   Aggerbeck, Martine ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d CENTRE DE GÉNÉTIQUE MOLÉCULAIRE   (France)

^e Gif/Orsay DNA Microarray Platform   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j UMR 7238   (France)

^k Programme Cartes d'Identite des Tumeurs CIT   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ACCURACY; ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER PATIENT; CLINICAL ARTICLE; DRUG EFFICACY; GENE EXPRESSION; GENE SEQUENCE; GENETIC REGULATION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; MALE; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREDICTION; TREATMENT FAILURE; TUMOR BIOPSY;

ADULT; AGED; CISPLATIN; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAXOIDS;

EID: 84867312948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047170     Document Type: Article

References (49)

1. Braakhuis BJ, Brakenhoff RH, Leemans CR, (2005) Second field tumors: a new opportunity for cancer prevention? Oncologist 10: 493-500.
2. Chen AY, Schrag N, Hao Y, et al. (2007) Changes in treatment of advanced oropharyngeal cancer, 1985-2001. Laryngoscope 117: 16-21.
3. The Department of Veteran Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324: 1685-1690.
4. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, et al. (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098.
5. Pignon JP, Bourhis J, Domenge C, Designé L, (2000) Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis chemotherapy on head and neck cancer. Lancet 355: 949-955.
6. Cmelak AJ, Li S, Goldwasser MA, Murphy B, Cannon M, et al. (2007) Phase II trial of chemoradiation for organ preservation in respectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 25: 3971-3977.
7. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, et al. (2007) TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357: 1705-1715.
8. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, et al. (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357: 1695-1704.
9. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, et al. (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12: 153-159.
10. Blons H, Gad S, Zinzindohoue F, Manière I, Beauregard J, et al. (2004) Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res 10: 2594-2599.
11. Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, Sanchez JJ, Ballestin C, et al. (2004) Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin Cancer Res 10: 8486-8492.
12. Nemeth Z, Szigeti K, Mathe M, Szabó G, Velich N, et al. (2005) Effect of induction chemotherapy on changes of laminin and syndecan expression in oral squamous cell carcinomas: a prospective, randomized, clinicopathologic and immunohistochemical study. J Craniofac Surg 16: 205-212.
13. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, et al. (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489-500.
14. Rickman DS, Millon R, De Reynies A, Thomas E, Wasylyk C, et al. (2008) Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene 27: 6607-6622.
15. Colombo J, Fachel AA, De Freitas Calmon M, Cury PM, Fukuyama EE, et al. (2009) Gene expression profiling reveals molecular marker candidates of laryngeal squamous cell carcinoma. Oncol Rep 21: 649-663.
16. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, et al. (2006) Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 24: 259-267.
17. Motoori M, Takemasa I, Yamasaki M, Komori T, Takeno A, et al. (2010) Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples. Int J Oncol 37: 1113-1120.
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655.
19. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 57: 289-300.
20. Marisa L, Ichanté JL, Reymond N, Aggerbeck L, Delacroix H, et al. (2007) MAnGO: an interactive R-based tool for two-colour microarray analysis. Bioinformatics 23: 2339-2341.
21. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, et al. (2001) Multiclass cancer diagnosis using tumor gene-expression signatures. Proceedings of the National Academy of Sciences USA 98: 15149-15154.
22. Fan R-E, Chen P-H, Lin C-J, (2005) Working set selection using second order information for training SVM. Journal of Machine Learning Research 6: 1889-1918.
23. Simon R, Lam A, Li MC, Nqan M, Menenzes S, et al. (2006) Analysis of gene expression data using BRB-Array Tools. Cancer Inform 3: 11-17.
24. Simon R, Radmacher MD, Dobbin K, McShane LM, (2003) Pitfalls in the analysis of DNA microarray data: Class prediction methods. Journal of the National Cancer Institute 95: 14-18.
25. Deleeuw J (1977) In Recent Developments in Statistics. 1. R. Barra,et al. eds. North-Holland. Amsterdam.
26. Kruskal JB, Wish M, Uslaner EM (2006) Multidimensional scaling. Sage Publications, Beverly Hills, California.
27. Spiess C, Meyer AS, Reissmann S, Frydman J, (2004) Mechanism of the eukaryotic chaperonin: protein folding in the chamber of secrets. Trends Cell Biol 14: 598-604.
28. Grantham J, Brackley KI, Willison KR, (2006) Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells. Exp. Cell Res 312: 2309-2324.
29. Coghlin C, Carpenter B, Dundas SR, Lawrie LC, Telfer C, et al. (2006) Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J Pathol 210: 351-357.
30. Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, et al. (2005) Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 65: 6789-6800.
31. Yamaguchi H, Condeelis J, (2007) Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 1773: 642-652.
32. Stirling PC, Cuéllar J, Alfaro GA, El Khadali F, Beh CT, et al. (2006) PhLP3 modulates CCT-mediated actin and tubulin folding via ternary complexes with substrates. J Biol Chem 28: 7012-7021.
33. Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, et al. (2005) cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol 55: 1-11.
34. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR, (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31: 164-172.
35. D'Souza B, Miyamoto A, Weinmaster G, (2008) The many facets of Notch ligands. Oncogene 27: 5148-5167.
36. Stansky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.
37. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, et al. (2005) Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 24: 4232-4242.
38. Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA, (2011) Identification of common differentially expressed genes in urinary bladder cancer. PLoS ONE 6: e18135.
39. Chen M, Tominaga K, Pereira-Smith OM, (2010) Emerging role of the MORF/MRG gene family in various biological processes, including aging. Ann N Y Acad Sci 1197: 134-141.
40. Banerjea A, Ahmed S, Hands RE, Huang F, Han X, et al. (2004) Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 3: 21-.
41. Wolin SL, Cedervall T, (2002) The La protein. Annu Rev Biochem 71: 375-403.
42. Sommer G, Rossa C, Chi AC, Neville BW, Heise T, (2011) Implication of RNA-binding protein La in proliferation, migration and invasion of lymph node-metastasized hypopharyngeal SCC cells. PLoS ONE 6: e25402.
43. Yokoyama A, Yamashita T, Shiozawa E, Nagasawa A, Okabe-Kado J, et al. (2004) MmTRA1b/phospholipid scramblase 1 gene expression is a new prognostic factor for acute myelogenous leukemia. Leuk Res 28: 149-157.
44. Lu B, Sims PJ, Wiedmer T, Moser AH, Shiqenaqa JK, et al. (2007) Expression of the phospholipid scramblase (PLSCR) gene family during the acute phase response. Biochim Biophys Acta 1771: 1177-1185.
45. Silverman RH, Halloum A, Zhou A, Dong B, Al-Zoghaibi F, et al. (2002) Suppression of ovarian carcinoma cell growth in vivo by the interferon-inducible plasma membrane protein, phospholipid scramblase 1. Cancer Res 62: 397-402.
46. Monteclaro FS, Vogt PK, (1993) A Jun-binding protein related to a putative tumor suppressor. Proc Natl Acad Sci U S A. 90: 6726-6730.
47. Workman P, Clarke PA, Al-Lazikani B, (2012) Personalized Medicine: Patient-Predictive Panel Power. Cancer Cell 21: 455-456.
48. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
49. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.